Octahydro-Cyclopentapyrrole-1-Carboxylic Acid Ethyl Ester

During the final amidation step in the synthesis of the angiotensin-converting enzyme inhibitor ramipril, the unprotected (S)-octahydrocyclopenta[b]pyrrole-2-carboxylic acid fragment is susceptible to rapid racemization at the α-carbon via a transient Schiff-base intermediate when the reaction temperature exceeds 78°C. The resulting loss of enantiomeric excess—commonly dropping from 99.5% ee to below 92% ee within 45 minutes at reflux in dichloromethane—forces a complete re-work of the diastereomeric salt resolution step. The ethyl ester of octahydro-cyclopentapyrrole-1-carboxylic acid functions as an N-protected building block that electronically withdraws electron density from the pyrrolidine nitrogen, elevating the pKa of the adjacent C–H bond and suppressing the deprotonation–reprotonation sequence responsible for epimerization. In a typical industrial coupling cycle conducted in a 500 L glass-lined reactor equipped with a retreat-blade impeller and jacket temperature control to ±1.5°C, the N-ethoxycarbonyl derivative is pre-activated with 1.05 molar equivalents of EDC·HCl and 1.10 equivalents of HOBt in DMF at 0–5°C before the addition of the dipeptide precursor. The addition ratio is calibrated to leave a residual 0.5–1.0% unreacted bicyclic component to minimize formation of the N-acylurea by-product, which co-elutes with the target compound on a standard C18 analytical column. After 16 hours of agitation, the batch is quenched with chilled water, extracted with ethyl acetate, and the organic layer is concentrated under vacuum at ≤40°C to avoid thermal deprotection. The final API, ramipril, must comply with European Pharmacopoeia monograph 10.0, which imposes a limit of ≤0.15% for the (R,S)-diastereomer. Perindopril erbumine, synthesized via an analogous route, is controlled under the same ICH Q3C residual solvent thresholds: the ethyl acetate concentration in the finished dosage form must be below 5000 ppm, and DMF below 880 ppm. Batch records from three consecutive commercial runs at a FDA-registered facility observed a mean process capability index Cpk of 1.48 for enantiomeric purity when the N-protecting strategy was applied.

What Distinguishes This Ester from Acyclic Proline Surrogates in Peptide Therapeutics?

Replacement of a flexible proline residue with the conformationally constrained octahydrocyclopenta[b]pyrrole scaffold alters the pyrrolidine ring pucker equilibrium. X-ray crystallography of model tripeptides incorporating the (2S,3aR,6aS)-octahydrocyclopenta[b]pyrrole-2-carboxylic acid unit shows an exclusively exo-puckered five-membered ring, compared to the 60:40 endo/exo population in unsubstituted proline. The ethyl ester serves as the commercial entry point for Fmoc-solid-phase peptide synthesis: the N-ethoxycarbonyl group is cleaved with 33% HBr in acetic acid or via catalytic hydrogenolysis over 10% Pd/C, and the exposed secondary amine is subsequently re-protected with Fmoc-OSu in aqueous sodium carbonate at pH 9.0–9.5. The resulting Fmoc-bicyclic amino acid is loaded onto Wang resin pre-swollen in DMF at a substitution level of 0.4–0.6 mmol/g. Each elongation cycle on a CEM Liberty Blue microwave peptide synthesizer uses 4.0 equivalents of the constrained amino acid activated with HATU and DIEA in N-methylpyrrolidone for 4 minutes at 75°C. A clinical synthesis campaign targeting a macrocyclic peptide inhibitor of the Keap1–Nrf2 protein–protein interaction applied this strategy: the octahydrocyclopentapyrrole ethyl ester was converted in situ to the Fmoc acid, and the final cyclic 14-mer demonstrated a dissociation constant of 12 nM by surface plasmon resonance. Residual palladium in the Fmoc monomer is controlled to ≤10 ppm per USP <232> / ICH Q3D Elemental Impurities Guidelines; batches that exceed this limit require an additional treatment with QuadraSil MP metal scavenger resin. The terminal pharmaceutical products encompassing this rigidified proline mimic are evaluated in Phase I protocols for fibrotic disorders, making the ethyl ester’s supply chain a subject of EMA Guideline EMA/CHMP/CVMP/QWP/450620/2016 on the qualification of starting materials.

Reaction calorimetry data from pilot-plant campaigns targeting dipeptidyl peptidase-4 (DPP-4) inhibitors indicate that the ethyl carbamate protective group on the octahydrocyclopentapyrrole nitrogen introduces a measurable thermal stability envelope. A Mettler-Toledo RC1e heat-flow calorimeter recorded an onset exotherm of −112 kJ/mol during the coupling of the N-ethoxycarbonyl bicyclic acid chloride with a fluorinated pyrrolidine fragment in tetrahydrofuran at −15°C. The heat release rate peaked at 38 W/kg within 90 seconds of reagent addition, necessitating a controlled dosing rate of 0.8 L/min through a peristaltic pump with a safety interlock tied to reactor temperature. The molar addition ratio is locked at 1.03:1 (acid chloride to aminopiperidine) to cap the adiabatic temperature rise at ΔT_ad 48°C, well below the decompression limit of the 12-m³ Hastelloy C-276 batch reactor equipped with a rupture disk rated for 1.1 MPa. Downstream, the coupled intermediate undergoes global deprotection with ethanolic HCl to remove the Boc and N-ethoxycarbonyl groups simultaneously, a step that generates isobutylene and carbon dioxide and requires a scrubber charged with 10% aqueous NaOH. The final molecule—a bicyclic DPP-4 inhibitor with an allosteric binding mode—achieves target selectivity over DPP-8 and DPP-9 of more than 2000-fold in enzymatic assays conducted per the US Pharmacopeia assay protocol for dipeptidyl peptidase inhibitors. Quality-control release of the octahydro-cyclopentapyrrole-1-carboxylic acid ethyl ester intermediate follows the analytical procedure in General Chapter 〈621〉 for chromatographic purity and a specific rotational test measured at 589 nm in methanol at 20 ± 0.5°C. A certificate of analysis typically reports identity by ¹H NMR (DMSO-d₆, δ 1.18 ppm, triplet, J = 7.1 Hz, ester methyl) and ¹³C NMR (δ 155.8 ppm, carbamate carbonyl), with acceptance criteria for total impurities ≤0.5% area by HPLC at 210 nm.

Kinetic Resolution of Racemates Using the Bicyclic Carbamate Moiety

Derivatization of the octahydrocyclopentapyrrole-1-carboxylic acid ethyl ester at the C-2 position with a sterically encumbered tertiary amide generates a nucleophilic catalyst suitable for the kinetic resolution of axially chiral biaryl compounds. When the N-ethoxycarbonyl group is retained, the carbamate oxygen participates in a bifurcated hydrogen bond with the incoming electrophile, orienting the substrate within a well-defined chiral pocket. In a typical preparative-scale resolution of 2-formyl-1,1′-binaphthalene derivatives, the racemic aldehyde is treated with 0.8 equivalents of bicyclic catalyst and acetic anhydride in toluene at −30°C. Over 6 hours, the (R)-enantiomer is preferentially acylated with a selectivity factor s = 52, while the (S)-alcohol remains unreacted. The process runs in a 50 L jacketed reactor configured with a cascade temperature loop and online ReactIR probe; the characteristic carbonyl stretch shift from 1710 cm⁻¹ to 1745 cm⁻¹ signals reaction completion. Vacuum distillation recovers the unreacted enantiomer, and the acylated adduct is hydrolyzed back to the enriched aldehyde using 2 M K₂CO₃ in methanol–water. The recovered bicyclic catalyst is re-purified by silica gel chromatography and can be reused across 12 consecutive cycles with only a 4% loss in selectivity. Compliance with ICH Q3D for residual metals is critical: the catalyst synthesis employs no heavy-metal reagents, and the only metal monitored is sodium (threshold ≤2500 μg/day per oral PDE). Validation of enantiomeric excess in the resolved product follows ASTM E2619-21 using a Chiralpak IG-3 column (4.6 × 150 mm, 3 μm) with a mobile phase of hexane–ethanol–trifluoroacetic acid (85:15:0.1) at 1.0 mL/min and detection at 254 nm.

Solid-phase peptide synthesis employing the Fmoc-protected octahydrocyclopenta[b]pyrrole-2-carboxylic acid—derived directly from the ethyl ester—provides access to lactam-bridged macrocycles that target integrin α_vβ₃ receptors overexpressed on tumor vasculature. The N-ethoxycarbonyl ester is first subjected to base-promoted hydrolysis with LiOH·H₂O (3.0 equivalents) in THF–water at 25°C to liberate the free N-protected amino acid, which is then directly coupled to 2-chlorotrityl chloride resin at a loading of 0.8 mmol/g with 5.0 equivalents of DIEA in dichloromethane. Chain elongation follows a standard Fmoc protocol, but the constrained bicyclic residue forces a cis-amide bond in the subsequent residue 78% of the time, as determined by 2D-NOESY of the linear precursor. Head-to-tail cyclization is achieved with PyAOP/HOAt in DMF at 0.5 mM concentration to suppress dimerization; the crude macrocycle is purified on a preparative HPLC system equipped with a C18 column (50 × 250 mm, 10 μm) eluting with a gradient of 0.1% TFA in water and acetonitrile. The terminal product, a cyclic pentapeptide containing the bicyclic amino acid, exhibits an IC₅₀ value of 8.6 nM against α_vβ₃ in a solid-phase competitive binding assay. The entire manufacturing chain for the peptide API must adhere to cGMP as defined in ICH Q7 §2.22 for the management of changes to starting material synthesis; any alteration to the ester supplier’s process—such as a shift in solvent from diethyl ether to methyl tert-butyl ether—triggers a full re-validation of the peptide purity profile, including testing for methyl pivalate residuals via headspace GC–MS.

Bridging Ligand Design for Asymmetric Transfer Hydrogenation

Deprotection of octahydro-cyclopentapyrrole-1-carboxylic acid ethyl ester with trimethylsilyl iodide in acetonitrile at 0°C yields the parent octahydrocyclopenta[b]pyrrole, which is subsequently alkylated with 1.1 equivalents of 2-picolyl chloride hydrochloride in the presence of K₂CO₃ to form an N,N-bidentate ligand precursor. This diamine, after complexation with [RuCl₂(p-cymene)]₂ in isopropanol at 80°C for 2 hours, generates a chiral ruthenium catalyst that promotes the asymmetric transfer hydrogenation of acetophenone derivatives with formic acid–triethylamine azeotrope. The ligand-to-metal ratio is fixed at 2.05:1, and the catalyst loading is 0.1 mol% for substrates with electron-withdrawing para substituents. A campaign conducted in a 100 L Hastelloy hydrogenation vessel operated at 30 bar H₂ and 40°C achieved 97.3% ee for (S)-1-(4-chlorophenyl)ethanol with a substrate-to-catalyst turnover number of 9200. The crude product is distilled through a wiped-film evaporator at 140°C and 0.5 mbar to afford pharmaceutical-grade intermediate with a GC purity exceeding 99.8%. Residual ruthenium is removed by treatment with a thiol-functionalized silica scavenger (Silicycle SiliaMetS Thiol) to ≤5 ppm, as required by the European Medicines Agency’s Guideline on the Specification Limits for Residues of Metal Catalysts. The ligand precursor itself—the purified N-ethoxycarbonyl ester—is routinely monitored for moisture content by Karl Fischer titration (limit ≤0.10% w/w) because water accelerates deprotection of the carbamate during storage and introduces batch-to-batch variability in the subsequent alkylation step.

In the manufacture of a Phase II clinical candidate targeting the voltage-gated sodium channel Na_v1.7 for neuropathic pain, the octahydrocyclopentapyrrole-1-carboxylic acid ethyl ester serves as the source of the rigid bicyclic core that occupies a hydrophobic sub-pocket defined by residues Tyr1537 and Trp1538. The synthesis proceeds through a Suzuki–Miyaura cross-coupling between a C-2 brominated derivative of the N-ethoxycarbonyl ester and an arylboronic acid pinacol ester using Pd(dppf)Cl₂ (0.05 equivalents) and K₃PO₄ (3.0 equivalents) in dioxane–water at 85°C. The molar ratio of the brominated bicyclic carbamate to the boronate is held at 1:1.2 to drive conversion beyond 98%, as incomplete coupling introduces a des-bromo impurity that is difficult to purge by crystallization. Reaction monitoring by UPLC at 230 nm tracks the disappearance of the starting ester; a hold step of 4 hours is triggered if the area percent of the bromo compound exceeds 0.8%. The isolated intermediate then undergoes acidic removal of the N-ethoxycarbonyl group with 6 M HCl in isopropanol, followed by reductive amination with paraformaldehyde and sodium triacetoxyborohydride to install the N-methyl group required for metabolic stability. The final API is formulated as a hydrochloride salt in an immediate-release tablet; the polymorphic form (Form A) is confirmed by X-ray powder diffraction against a reference pattern stored in the regulatory master file. The starting material, octahydro-cyclopentapyrrole-1-carboxylic acid ethyl ester, must be manufactured under an ICH Q11-compliant certificate of suitability and pass a genotoxic impurity evaluation per ICH M7 Addendum (≤1.5 μg TTC for an anticipated treatment duration of 6–12 months). A risk assessment examined potential carryover of ethyl chloroformate, used in the industrial acylation of the parent amine, and set a purge factor of ≥1000 based on the downstream aqueous workup and distillation.